New RSV vaccine for older adults can result in individual and societal cost savings, benefits
Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research. The study conducted by researchers at the University of Michigan and the U.S. Centers for Disease Control and Prevention and published in the journal Vaccine, evaluated newly approved RSV … Read more
